• PURPOSE: To identify visually significant spectral-domain optical coherence tomography (SD-OCT) features of epiretinal membranes (ERM) in patients with uveitis. • DESIGN: Retrospective cohort and cross-sectional study. • METHODS: Eighty consecutive eyes with uveitis and SD-OCT-documented ERM were included. Clinical data were collected at the time of diagnosis of ERM and at the final visit. SD-OCT images at the last visit were evaluated to identify fovea and ERM configuration and structural changes. Changes of 10% and 20% in central subfield thickness between initial and last SD-OCT were calculated and correlated with visual acuity (VA). An ERM thickness map was created using validated SD-OCT grading software. • RESULTS: VA improved significantly in eyes with more than 12 months of follow-up (P = .03). Although inflammation activity and medical treatment methods were no different in eyes with more or less than 12 months of follow-up, 16 eyes in the subset with longer follow-up underwent cataract extraction and intraocular lens implantation. Kaplan-Meier analysis demonstrated few vision losses during the follow-up period. Change in central subfield thickness did not correlate with VA. Foveal center involvement (P < .001), focal attachment of the ERM (P = .003), and foveal inner segment and outer segment junction disruption (P = .006) were associated independently with lower VA. ERM was thinner in eyes with 20/40 or better VA (4.6 ± 0.6 μm) compared with eyes with VA of less than 20/200 (P = .02). Longer duration of ERM was associated with thicker ERM (P < .05). • CONCLUSIONS: In most eyes with uveitis and ERM, VA remains stable if ocular inflammation and comorbidities are addressed appropriately.
Bibliographical noteFunding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and the following were reported. Dr Sadda receives research support from Carl Zeiss Meditec, Optos, and Optovue; shares in royalties from intellectual property licensed to Topcon Medical Systems from the Doheny Eye Institute; serves as a consultant for Heidelberg Engineering and Optos; and is supported by Research to Prevent Blindness Physician Scientist Award. Publication of this article was supported in part by Vision Core Grant EY03040 from the National Institutes of Health, Bethesda, Maryland. Involved in Design of study (N.A.R., H.N.); Conduct of study (N.A.R., H.N., S.S., F.M.H.); Collection (N.A.R., H.N.) and management, analysis, and interpretation (N.A.R., H.N., L.D.) of the data; and Preparation, review, and approval of the manuscript (N.A.R., H.N., L.D., S.S.). The study protocol encompassing retrospective data review from the charts with waiver for informed consent was approved by Institutional Review Board of the University of Southern California, Los Angeles, California. The study was in compliance with Health Insurance Portability and Accountability Act regulations.